Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: 3 - You Need To See This

2 Under-The-Radar Stocks to Buy Now Before Wall Street Catches On

With the combination of still-higher rates and widespread recessionary concerns, the stock market will likely stay under pressure for the near term. Therefore, it could be wise to buy fundamentally strong stocks Corcept Therapeutics (CORT) and Arcos Dorados (ARCO) that are flying under the radar now before Wall Street catches…

StockNews.com

2 Biotech Stocks Under $100 to Buy Now

The biotech industry flourished amid the pandemic, and lucrative federal investments are expected to drive further growth in the sector. Moreover, amid evolving variants of Coronavirus, the biotech industry is expected to remain in the limelight. Given the sound prospects of the industry, quality biotech stocks Gilead Sciences (GILD) and…

StockNews.com

3 Biotech Stocks to Accumulate During the Bear Market

2022 has been a challenging year for investors due to the combination of inflation and a slowing economy. Biotech stocks could be a place where investors can find outperformance given their low valuations and strong long-term fundamentals. Amgen (AMGN), Corcept Therapeutics (CORT), and Regneron (REGN) are 3 to consider.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Growing institutional interest in community housing

Large investors see an opportunity in the $4 billion in housing supplements paid out annually, the government sees a win.

Newsroom.co.nz

3 Biotech Stocks to Beat the Bear Market

2022 is a challenging year for the market. After battling surging inflation for the first six months, another threat is emerging with rising recession risk. Biotech stocks could be a place where investors can find outperformance given their low valuations and strong long-term fundamentals.

StockNews.com

4 Biotech Stocks to Add to Your Watchlist

The surging demand for viable drugs and vaccines, advanced therapies, and increasing investments in research and development make the biotech industry’s prospects bright. Thus, it could be wise to invest in fundamentally sound biotech stocks Amgen (AMGN), Vertex Pharmaceuticals (VRTX), BioNTech (BNTX), and Corcept Therapeutics (CORT).

StockNews.com

Corcept Therapeutics's Return On Capital Employed Overview

According to Benzinga Pro, during Q4, Corcept Therapeutics (NASDAQ:CORT) earned $32.05 million, a 5.19% increase from the preceding quarter. Corcept Therapeutics also posted a total of $98.82 million in sales, a 2.8% increase since Q3.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Recap: Corcept Therapeutics Q4 Earnings

Corcept Therapeutics (NASDAQ:CORT) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals Incorporated

65 stories

CORT

58 stories

Arcos Dorados Holdings Inc

22 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.